MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$131,971K
Free Cash flow
-$84,146K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sales of marketable securities
Equity-based compensation
Proceeds from exercise of option...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Other non-cash items, net
Investment in equity securities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-91,154
-122,931
-130,613
-106,441
Depreciation and amortization
4,280
4,319
5,661
4,433
Equity-based compensation
17,316
16,324
18,076
16,604
Other non-cash items, net
13,563
-8,800
8,314
10,139
Amortization of debt issuance costs
848
-
-
-
Acquired in-process research and development
2,473
-
0
0
Accounts receivable
0
0
0
0
Prepaid expenses and other assets
841
247
-3,852
-212
Accounts payable and accrued expenses
-5,306
-13,015
4,421
12,175
Deferred revenue
-155
-427
2,153
-834
Operating lease assets and liabilities
-1,543
-1,521
-1,343
-1,446
Other liabilities, net
4,147
-199
13,554
802
Net cash used in operating activities
-83,498
-108,897
-92,553
-84,634
Purchases of property, plant and equipment
648
504
517
74
Investment in equity securities
8,728
4,615
0
0
Sale of equity securities
-
-
702
-
Purchases of in-process research and development
2,473
-
0
0
Purchases of marketable securities
206,299
746,089
262,973
334,086
Maturities of marketable securities
-8,506
192,759
299,987
214,934
Sales of marketable securities
170,995
147,706
-
-
Net cash (used in) provided by investing activities
-55,659
-410,743
37,199
-119,226
Proceeds from issuance of the notes
0
600,000
-
-
Issuance costs and discounts associated with the notes
1,122
13,528
-
-
(payments) proceeds from issuance of common shares, net of issuance costs
0
-722
111,491
278,105
Proceeds from exercise of options and espp contributions, net of issuance costs
8,302
6,158
4,923
18,661
Net cash provided by financing activities
7,180
591,908
116,414
296,766
Effect of exchange rate changes on cash
6
-32
1
-27
Decrease in cash
-131,971
72,236
61,061
92,879
Cash, cash equivalents and restricted cash, beginning of period
431,314
359,078
298,017
309,776
Cash, cash equivalents and restricted cash, end of period
299,343
431,314
359,078
298,017
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
options and espp...
$8,302K
(90.76%↑ Y/Y)
Net cash provided by
financing activities
$7,180K
(-44.11%↓ Y/Y)
Effect of exchange rate
changes on cash
$6K
(-95.04%↓ Y/Y)
Canceled cashflow
$1,122K
Decrease in cash
-$131,971K
(-26.12%↓ Y/Y)
Canceled cashflow
$7,186K
Equity-based compensation
$17,316K
(-54.21%↓ Y/Y)
Depreciation and
amortization
$4,280K
(-54.40%↓ Y/Y)
Other liabilities,
net
$4,147K
(141.07%↑ Y/Y)
Acquired in-process
research and development
$2,473K
(-97.43%↓ Y/Y)
Amortization of debt issuance
costs
$848K
Sales of marketable
securities
$170,995K
Issuance costs and
discounts associated with...
$1,122K
Net cash used in
operating activities
-$83,498K
(50.25%↑ Y/Y)
Net cash (used in)
provided by investing...
-$55,659K
(-210.83%↓ Y/Y)
Canceled cashflow
$29,064K
Canceled cashflow
$170,995K
Net loss
-$91,154K
(73.54%↑ Y/Y)
Purchases of marketable
securities
$206,299K
(-49.82%↓ Y/Y)
Other non-cash items,
net
$13,563K
(167.25%↑ Y/Y)
Accounts payable and
accrued expenses
-$5,306K
(-118.75%↓ Y/Y)
Operating lease assets and
liabilities
-$1,543K
(36.27%↑ Y/Y)
Prepaid expenses and
other assets
$841K
(15.68%↑ Y/Y)
Deferred revenue
-$155K
(90.97%↑ Y/Y)
Investment in equity
securities
$8,728K
(-10.02%↓ Y/Y)
Maturities of marketable
securities
-$8,506K
(-101.71%↓ Y/Y)
Purchases of in-process
research and development
$2,473K
(-90.11%↓ Y/Y)
Purchases of property,
plant and equipment
$648K
(100.62%↑ Y/Y)
Buy us a coffee
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)